Zuckerberg San Francisco General Hospital and Trauma Center
Welcome,         Profile    Billing    Logout  
 22 Trials 
47 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rugo, Hope
CALGB-40503, NCT00601900: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
3
394
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Laboratory Biomarker Analysis, Letrozole, CGS 20267, CGS-20267, CGS20267, Femara, Fempro, Questionnaire Administration, Tamoxifen Citrate, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI 46474, ICI-46474, ICI46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Tamoxifeni Citras, Zemide
National Cancer Institute (NCI)
Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
06/14
05/25
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
NCT03562637 / 2018-001438-16: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Recruiting
3
668
Europe, US, RoW
adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
OBI Pharma, Inc, OBI Pharma, Inc.
Triple Negative Breast Cancer
12/25
12/27
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
FOENIX-MBC2 TAS-120-201, NCT04024436 / 2019-001164-30: A Study of TAS-120 in Patients With Metastatic Breast Cancer

Completed
2
168
Europe, Canada, US
Futibatinib, TAS-120, Futibatinib plus Fulvestrant
Taiho Oncology, Inc., Taiho Pharma Europe Limited, TAIHO ONCOLOGY INC.
Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification
05/23
10/24
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
NCT03990896: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Recruiting
2
30
US
Talazoparib, Talzenna
Massachusetts General Hospital, Pfizer
Breast Cancer
07/25
12/25
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
NCT03941730: Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting
2
5
US
Biopsy, BIOPSY_TYPE, Bx, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Therapeutic Estradiol, 17 Beta-Estradiol, Aquadiol, Climara, Dimenformon, Diogyn, Diogynets, Estrace, ESTRADIOL, Estraldine, Oestradiol, Ovocylin, Progynon, Vagifem
Mayo Clinic, National Cancer Institute (NCI)
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
07/26
07/26
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
TBCRC 044, NCT03095352: Pembrolizumab with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

Completed
2
70
US
Pembrolizumab, Carboplatin, Ribocarbo, Trastuzumab
Hope Rugo, MD, Mayo Clinic, Johns Hopkins University, Translational Breast Cancer Research Consortium, Massachusetts General Hospital, Merck Sharp & Dohme LLC
Breast Cancer, Chest Wall Disease
11/24
11/24
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 Vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
Cornerstone001, NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
2
10
US, RoW
AST-301(pNGVL3-hICD), AST-301, rhuGM-CSF, Leukine, Sargramostim, Placebo, Normal Saline, Pembrolizumab, Keytruda, Capecitabine, Xeloda
Aston Sci. Inc.
Breast Cancer
05/24
05/24
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
2
201
US
Enzalutamide, Mifepristone, TPC
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics
Metastatic Breast Cancer
10/27
10/27
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/24
08/26
NCT06215469: Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)

Recruiting
N/A
40
US
Amma Portable Scalp Cooling System (PSCS), Portable Scalp Cooling System (PSCS), Questionnaires
University of California, San Francisco, Cooler Heads Care Inc.
Breast Cancer, Early-stage Breast Cancer, Hair Loss, Alopecia, Chemotherapy-induced Alopecia
08/25
08/25
ENCORE, NCT06774027: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Not yet recruiting
N/A
100
US
Specimen collection, Biospecimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Non-Investigational ADC, Medical Record Review, Medical Chart Review
University of California, San Francisco, Translational Breast Cancer Research Consortium, Gilead Sciences, Johns Hopkins University
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
12/30
12/30
Arjomandi, Mehrdad
NCT02797275: Secondhand Smoke Respiratory Health Study

Active, not recruiting
4
107
US
Albuterol, ProAir, Placebo, Placebo obtained from Teva
University of California, San Francisco, Flight Attendant Medical Research Institute
Secondhand Smoke, Air Trapping, Tobacco, Airflow Limitation, Hyperinflation, Obstructive Lung Disease
12/24
12/24
NCT04715568: Secondhand Tobacco Smoke and Cardiovascular Disease

Recruiting
4
100
US
Losartan, Cozaar, Angiotensin II Receptor Blocker, Antihypertensive, Placebo, Inactive drug
University of California, San Francisco, Flight Attendant Medical Research Institute
Cardiovascular Diseases, Hypertension
12/25
12/25
Pre-COPD Pilot, NCT04722835: Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

Recruiting
N/A
40
US
Bronchoscopy with Bronchoalveolar Lavage (BAL), Albuterol Administration, Peak Flow Measurement, Pulmonary Function Test (with Spirometry), Blood draw, Medical Health and Symptom Questionnaires, Physical Exam
University of California, San Francisco, United States Department of Defense
Copd, Smoking, Tobacco Use
12/22
12/22
CO3PD, NCT04669743: Innate Immunity in Ozone-induced Airway Inflammation in COPD

Active, not recruiting
N/A
72
US
Ozone exposure
University of California, San Francisco
Pulmonary Disease, Chronic Obstructive, Airway Disease, COPD Exacerbation, Pollution; Exposure, Pollution Related Respiratory Disorder
10/24
10/24
NCT03774758: Biomarkers for Risk Stratification in Lung Cancer

Recruiting
N/A
590
US
Guardant Health ct-DNA LUNAR assay, Liquid biopsy Using NGS to Assay high-Risk patients
University of California, San Francisco, Northern California Institute of Research and Education, Guardant Health, Inc.
Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
12/24
12/24
Nagaraj, Gayathri
NCT03598426: Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity

Recruiting
3
270
US
Dexamethasone, Decadron
Loma Linda University
Hypersensitivity Reactions
06/25
06/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer

Recruiting
1/2
52
US
Evexomostat, SDX-7320
SynDevRx, Inc.
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
03/26
09/26
NCT03272919: Chemotherapy Induced Peripheral Neuropathy (CIPN)

Completed
N/A
44
US
Arm 1: Investigational INF, Arm 2: standardized muscle stretching and strength
Loma Linda University
Chemotherapy-induced Peripheral Neuropathy
05/22
05/22
Thakur, Neeta
CARE, NCT05259436: Collaborative Approach to Examining Adversity and Building Resilience Study

Recruiting
N/A
300
US
Caregiver-child Intervention, Enhanced Primary Care
University of California, San Francisco, Lifelong Medical Care, UCSF Benioff Children's Hospital Oakland, Santa Barbara Neighborhood Clinics, University of California, Santa Barbara, Futures Without Violence
Early Life Adversity, Caregiver Stress
04/24
04/24
NCT05572632: Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD

Recruiting
N/A
387
US
COPD Wellness, COPD Wellness Plus+, Usual Care
University of California, San Francisco, National Heart, Lung, and Blood Institute (NHLBI)
COPD (Chronic Obstructive Pulmonary Disease)
12/26
06/27
Sarkar, Urmimala
IMPACTT, NCT06191185: IMProving Adherence to Colonoscopy Through Teams and Technology

Recruiting
N/A
2000
US
BPB, No PIN, BPB, PIN, No BPB, PIN, No BPB, No PIN
University of California, San Francisco, National Institutes of Health (NIH), National Cancer Institute (NCI)
Colon Cancer, Cancer Colorectal, Colorectal Cancer
03/27
03/27
CHARMED, NCT06113458: Comparing Hypertension Remote Monitoring Evaluation Redesign

Enrolling by invitation
N/A
2500
US
Standard and One-time Training, Standard and Practice Facilitation, High-intensity and One-time Training, High-intensity and Practice Facilitation
University of California, San Francisco, Patient-Centered Outcomes Research Institute
Hypertension
04/28
07/28
Kornblith, Lucy
ACTIV-4, NCT04505774 / 2020-004285-19: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Completed
4
3591
Europe, US, RoW
theraputic heparin, unfractionated heparin, Enoxaparin, Dalteparin, Tinzaparin, Heparin, prophylactic heparin, enoxaparin, dalteparin, Fondparinux, P2Y12, Ticagrelor, Prasugrel, Clopidogrel, Crizanlizumab Injection, SGLT2 inhibitor, dapagliflozin, empagliflozin, canagliflozin, ertugliflozin
Matthew Neal MD, National Heart, Lung, and Blood Institute (NHLBI)
Covid19
08/23
01/24
CASA RELAX, NCT05966454: Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure - UCSF

Recruiting
4
145
US
Multiple standard of care antibiotics for appendicitis, at physicians' discretion
University of California, San Francisco
Appendicitis
06/25
06/25
CriSP-HS, NCT04667468: Cold Stored Platelet in Hemorrhagic Shock

Completed
2
200
US
Cold Stored Platelets (CSP), Standard Care
Jason Sperry, United States Department of Defense
Trauma, Hemorrhage
10/23
11/23
NCT06654193: Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Not yet recruiting
1/2
70
US
Allogeneic HB-adMSCs, Normal Saline
Hope Biosciences, The University of Texas Health Science Center, Houston, University of California, San Francisco, University of Alabama at Birmingham
Acute Kidney Injury
01/28
01/28
NCT03682757: Post-Injury Platelet Biology: Mechanisms and Outcomes

Completed
N/A
367
US
University of California, San Francisco, University of Colorado, Denver, University of Utah, University of California, Berkeley, National Institute of General Medical Sciences (NIGMS)
Wound and Injuries, Blood Platelets, Endothelium
09/23
09/23
Hendrickson, Carolyn M
NCT06521502: The APS Phenotyping Study

Recruiting
N/A
4000
US
Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan
Vanderbilt University Medical Center
ARDS, Sepsis, Pneumonia
04/28
04/28
EquiOx, NCT05554510: Pulse Oximetry Errors in Hospitalized Patients Across Varying Skin Pigmentation

Recruiting
N/A
800
US
Observational
University of California, San Francisco, Food and Drug Administration (FDA)
Hypoxemia, Pulse Oximetry, Skin Pigment
10/24
10/24
Abrham, Yorusaliem
Pre-COPD Pilot, NCT04722835: Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

Recruiting
N/A
40
US
Bronchoscopy with Bronchoalveolar Lavage (BAL), Albuterol Administration, Peak Flow Measurement, Pulmonary Function Test (with Spirometry), Blood draw, Medical Health and Symptom Questionnaires, Physical Exam
University of California, San Francisco, United States Department of Defense
Copd, Smoking, Tobacco Use
12/22
12/22
Fernandez, Xuan Duong
CASPER, NCT03911492: Canadian-American Spinal Cord Perfusion Pressure and Biomarker Study

Recruiting
N/A
100
Canada, US
SCPP Management => 65 mmHg
University of British Columbia, Rick Hansen Institute
Acute Spinal Cord Injury, Acute Spinal Paralysis, Spinal Cord Injuries, SPINAL Fracture
03/25
12/25
DiGiorgio, Anthony
CASPER, NCT03911492: Canadian-American Spinal Cord Perfusion Pressure and Biomarker Study

Recruiting
N/A
100
Canada, US
SCPP Management => 65 mmHg
University of British Columbia, Rick Hansen Institute
Acute Spinal Cord Injury, Acute Spinal Paralysis, Spinal Cord Injuries, SPINAL Fracture
03/25
12/25
NCT05653206: Incomplete Cervical SCI Without Instability

Recruiting
N/A
50
Europe, Canada, US, RoW
Nonsurgical treatment, Surgical treatment
AO Foundation, AO Spine
Cervical Spinal Cord Injury
05/26
08/27
Sohn, Jae Ho
NCT05342675: Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy

Recruiting
N/A
126
US
Rapid Rollover
University of California, San Francisco
Lung Cancer, Pneumothorax
04/24
06/24
Wu, Xiao
NCT05342675: Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy

Recruiting
N/A
126
US
Rapid Rollover
University of California, San Francisco
Lung Cancer, Pneumothorax
04/24
06/24

Download Options